Generic Sitagliptin vs. Brand Januvia: Why One 2026 Part D Plan Charges $684 Per Year and Another Charges $1,622 for the Same Diabetes Drugs
Meet Margaret — and Why Her $0-Premium Plan Is Not the Bargain It Looks Like
Margaret is 67 years old. She takes three medications every day:
- Metformin ER 750mg (twice daily, generic) — for Type 2 diabetes
- Atorvastatin 40mg (once daily, generic) — for high cholesterol
- Januvia 100mg (once daily, brand) — as a second diabetes agent when metformin alone wasn't enough
She is enrolled in a Part D plan with a $0 monthly premium. She chose it during last year's Open Enrollment because, well — zero dollars a month is hard to argue with.
She is paying $1,622 per year for those three drugs.
Her neighbor, on a plan with a $52 monthly premium, is paying $684 per year for nearly the same drug list — because his plan places generic sitagliptin (the generic version of Januvia, available since late 2023) on Tier 1, and his premium is the only real cost he sees.
That $938 annual difference is not a trick or a loophole. It is the direct, predictable result of formulary tier placement — and it is exactly what Pelandri's analysis of CMS formulary data is designed to surface before you make this decision blindly.
What "Formulary Tier" Actually Means (In Plain English)
A formulary is your plan's master drug list. Every covered drug sits on a tier, and the tier determines your copay. Here is how the 2026 standard tier structure looks across most Part D plans:
| Tier | Drug Category | Typical 2026 Copay |
|---|---|---|
| Tier 1 | Preferred generics | $0 – $5/fill |
| Tier 2 | Non-preferred generics | $5 – $15/fill |
| Tier 3 | Preferred brand | $42 – $50/fill |
| Tier 4 | Non-preferred brand | $80 – $100/fill |
| Tier 5 | Specialty drugs | 25–33% coinsurance |
The exact tiers vary by plan — that is the whole problem. The same drug can sit on Tier 1 on Plan A and Tier 4 on Plan B. And because Medicare has no rule requiring plans to place a drug on any particular tier (only that the formulary meets certain coverage requirements), the spread can be enormous.
For Margaret's drugs, here is what that looks like across three real-world plan profiles for 2026, based on Pelandri's review of CMS Part D formulary files:
The Annual Cost Math: Three Plans, Same Three Drugs
Margaret's drug list:
- Metformin ER 750mg (30-day supply × 12)
- Atorvastatin 40mg (30-day supply × 12)
- Januvia 100mg (brand) OR generic sitagliptin 100mg (30-day supply × 12)
Plan A — The $0-Premium Plan That Isn't Free
| Line Item | Amount |
|---|---|
| Monthly premium | $0 |
| Annual premium | $0 |
| Deductible (Tier 3-5 only) | $590 |
| Metformin ER — Tier 1, deductible waived | $3/month × 12 = $36 |
| Atorvastatin — Tier 2, deductible waived | $8/month × 12 = $96 |
| Januvia brand — Tier 4, subject to deductible | $590 deductible + $90/month × 10 months = $1,490 |
| Total annual cost | $1,622 |
The deductible math on Januvia: Merck's negotiated price for a 30-day supply runs roughly $340–370 after plan pricing. Margaret burns through the $590 deductible in under two fills, then pays the Tier 4 copay of $90/month for the remaining ten months. That is $1,490 just for one diabetes drug.
Plan B — Moderate Premium, Preferred Brand Tier
| Line Item | Amount |
|---|---|
| Monthly premium | $38 |
| Annual premium | $456 |
| Deductible (waived for all covered drugs on this plan) | $0 |
| Metformin ER — Tier 1 | $0/month = $0 |
| Atorvastatin — Tier 1 | $0/month = $0 |
| Januvia brand — Tier 3, preferred brand | $47/month × 12 = $564 |
| Total annual cost | $1,020 |
Better — $602 less than Plan A. The higher premium more than pays for itself through lower drug costs.
Plan C — Generic Sitagliptin, Tier 1 Placement
| Line Item | Amount |
|---|---|
| Monthly premium | $52 |
| Annual premium | $624 |
| Deductible (waived for Tier 1/2) | $0 |
| Metformin ER — Tier 1 | $0/month = $0 |
| Atorvastatin — Tier 1 | $0/month = $0 |
| Generic sitagliptin 100mg — Tier 1 | $5/month × 12 = $60 |
| Total annual cost | $684 |
Plan C costs $938 less than Plan A per year — even though it has the highest monthly premium. The switch from brand Januvia to generic sitagliptin is doing most of the heavy lifting here, but the plan's Tier 1 placement of the generic is what makes the math work.
This is precisely the kind of analysis Pelandri runs for your specific drug list — because the right answer depends entirely on which drugs you take and how each plan tiers them.
Why Generics Don't Automatically Save You Money (The Prior Authorization Problem)
Here is where things get complicated — and where a KFF Health News investigation into West Virginia's prior authorization crisis becomes directly relevant.
KFF reported in March 2026 on the case of Eric Tennant, a West Virginian whose insurer repeatedly denied cancer treatment recommended by his oncologist. His widow fought back, and West Virginia's governor signed a bill restricting prior authorization abuse. The story is about commercial insurance, but the same prior authorization dynamic exists in Medicare Part D — and it can block your access to drugs your doctor already prescribed.
In Part D, prior authorization (PA) and step therapy requirements work like this:
- Prior authorization: Your plan requires your doctor to submit paperwork proving the drug is medically necessary before they'll cover it. Common targets include brand drugs, specialty drugs, and drugs with cheaper alternatives available.
- Step therapy: Your plan requires you to try a cheaper drug first — and document that it failed — before they'll cover the drug your doctor originally prescribed. DPP-4 inhibitors like sitagliptin are a frequent step therapy target: many plans want documentation that metformin alone was tried first.
For Margaret, this creates a scenario worth understanding:
If she is newly adding sitagliptin to her regimen and her doctor writes the prescription, some Part D plans will reject it at the pharmacy until the doctor submits a prior authorization form documenting metformin failure. This is not denial — it is a coverage delay that can stretch 1–3 weeks. For a diabetes medication that controls blood sugar, that delay has real health consequences.
The irony: switching from brand Januvia to generic sitagliptin often avoids prior authorization on most 2026 plans, because the generic is preferred and the PA requirement targets the brand name specifically (to push patients toward the generic). So in this case, taking the generic version that saves you money is also the version that involves less administrative friction.
The lesson: Before you enroll, check not just the tier but the formulary restrictions — prior authorization flags, step therapy requirements, and quantity limits. These are in every plan's formulary document, but they are buried in dense tables. Our post on Ozempic and GLP-1 formulary tiers walks through how step therapy requirements hit GLP-1 drugs particularly hard in 2026.
The $2,000 Cap: Does Margaret Hit It?
Under the Inflation Reduction Act, 2026 Part D has a hard $2,000 true out-of-pocket (TrOOP) cap. Once you've paid $2,000 in covered drug costs out of pocket, you pay $0 for the rest of the year.
On Plan A, Margaret's out-of-pocket spending is $1,622 — she does not hit the cap. If she were also taking a higher-cost specialty drug (a biologic for rheumatoid arthritis, for instance, or Eliquis for atrial fibrillation), she might hit $2,000 and the calculus would change dramatically. Our deep dive on how the $2,000 cap affects Eliquis and Entresto users shows how high-cost drug combinations interact with the cap.
For Margaret, the cap is not the lever — the tier placement is.
You can model exactly when (and whether) you'd hit the $2,000 cap for your own drug list at Pelandri.
What This Means for Lower-Income Beneficiaries
A separate thread worth noting: KFF reported in 2026 that roughly 17,000 federally funded community health centers stand to lose up to $32 billion in funding under proposed federal budget cuts. These clinics serve a significant share of dual-eligible beneficiaries — people who qualify for both Medicare and Medicaid — who rely on FQHC (Federally Qualified Health Center) 340B pricing for affordable prescriptions alongside their Part D plan.
If you or a family member qualifies for Extra Help (also called the Low-Income Subsidy), the math changes further. Extra Help recipients pay $0–$11.20 per fill for most drugs regardless of tier placement — effectively eliminating the tier penalty. If income is a factor, checking Extra Help eligibility before choosing a plan is step one, not an afterthought.
Our guide to Extra Help, preferred pharmacies, and tier exceptions for Eliquis walks through the eligibility thresholds and how to apply.
The Generic Switch Is Worth Having the Conversation
If you or a family member is taking brand Januvia, ask your doctor whether generic sitagliptin is appropriate. As of 2026, multiple manufacturers produce FDA-approved generic sitagliptin 100mg. The active ingredient and dosage are identical. The cost difference — particularly on plans that place the generic on Tier 1 — can exceed $900 per year.
This is not a decision to make without your doctor. But it is absolutely a question worth asking before you lock in a plan for the next 12 months. As our analysis of metformin, atorvastatin, and Eliquis across Part D plans shows, the combination of generic substitution and the right formulary tier placement routinely cuts annual drug costs in half.
Before the March 31 Deadline: What to Do Right Now
The Special Enrollment Period that opened in January closes March 31, 2026. After that, you cannot switch Part D plans until October's Open Enrollment — which means a wrong plan choice locks in for most of the year.
Before that deadline closes, run your actual drug list through a plan comparison tool. Not a premium comparison — a total annual cost comparison that accounts for your specific drugs, dosages, preferred pharmacy, and tier placement. The premium is maybe 30% of the story. Formulary tiers, deductible applicability, prior authorization requirements, and generic availability determine the rest.
Pelandri builds that full-cost comparison for your drug list — so you see the $684 plan vs. the $1,622 plan side by side, not just the $0 vs. $52 monthly premium.
Margaret's neighbor figured this out. Now Margaret is working on switching before March 31. There is still time to do the same.
Sources
- Readers Sound Off on Wage Garnishment, Work Requirements, and More — KFF Medicare
- After Man’s Death Following Insurance Denials, West Virginia Tackles Prior Authorization — KFF Medicare
- Trump’s One Big Beautiful Bill Act Darkens Outlook for Government-Backed Clinics — KFF Medicare
- Listen to the Latest ‘KFF Health News Minute’ — KFF Medicare
- Trump’s Hunt for Undocumented Medicaid Enrollees Yields Few Violators — KFF Medicare